☆ 4.7 Letter

Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor for 24 Weeks or Longer in People with Cystic Fibrosis and One or More F508del Alleles: Interim Results of an Open-Label Phase 3 Clinical Trial

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2021)

Get Full Text
Add to Collection

Journal

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
Volume 203, Issue 3, Pages 381-385

Publisher

AMER THORACIC SOC
DOI: 10.1164/rccm.202008-3176LE

Keywords

-

Categories

Critical Care Medicine Respiratory System

Funding

  1. Vertex Pharmaceuticals Inc.

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.